Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Filings indexed 2,379 across all filing types
Latest filing 2025-05-21 Regulatory Filings
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-05-21 English
Regulatory Filings 2025
Regulatory Filings
2025-05-21 English
FORM 4
Director's Dealing
2025-05-19 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 19, 2025, by Vertex Pharmaceuticals Incorporated. The key content is the announcement of a new stock repurchase program (2025 Repurchase Program) authorized by the Board of Directors, including details about the amount authorized and previous repurchase programs. There are no financial statements or detailed financial analysis present, only an announcement of a capital activity (stock repurchase authorization). The document length is 3570 characters, which is relatively short and focused on a specific capital/financing update. According to the classification rules, announcements about company fundraising, financing activities, or capital structure changes such as share repurchase programs fall under Capital/Financing Update (CAP). Therefore, the correct classification is CAP with high confidence.
2025-05-19 English
FORM 4
Director's Dealing
2025-05-15 English
Regulatory Filings 2025
Regulatory Filings
2025-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.